Inhibition of the PI3K catalytic subunit p110γ, which is expressed in leukocytes and some HNSCCs, has shown promise in treating HNSCC; with clinical trials underway to gauge its effectiveness. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.